Patents Assigned to CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS
-
Patent number: 11814650Abstract: Method for expanding stemness and differentiation potential of pluripotent cells. The invention is based on the finding that increasing micro RNA-203 levels in induced pluripotent stem (iPSCs) or embryonic stem (ESCs) cells improves the quality cell fate potential and ability of these cells to differentiate into multiple cell lineages and to reach further maturation properties without interfering with their self-renewal properties. This effect is mediated through the mi R-203-dependent control of de novo DNA methyltransferases Dnmt3a and Dnmt3b, which in turn regulate the methylation landscape of pluripotent cells. The effect can be achieved by overexpression of micro RNA-203 or by adding micro RNA-203 or analogues thereof to the cell culture medium and can be observed using a variety of cellular and in vivo models.Type: GrantFiled: May 25, 2018Date of Patent: November 14, 2023Assignee: FUNDACIÓN DEL SECTOR PÚBLICO ESTATAL CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (F.S.P. CNIO)Inventors: Marcos Malumbres, Maria Salazar-Roa, Marianna Trakala, Mónica Alvarez-Fernandez
-
Patent number: 11536724Abstract: The invention relates to a collection of signature peptides representing at least 10 proteins for use in cancer diagnosis and/or prognosis, to an artificial protein comprising signature peptides representing at least 10 proteins and to a nucleic acid construct encoding for such an artificial protein. The invention further relates to a collection of at least 10 proteins for use in cancer diagnosis and/or prognosis. Additionally, the invention relates to a method for cancer diagnosis and/or prognosis comprising the step of analyzing at least 10 proteins in a urine sample of a subject. Finally, the invention relates to an immunoassay product comprising antibodies for detecting at least 10 proteins.Type: GrantFiled: December 23, 2016Date of Patent: December 27, 2022Assignees: POLYQUANT GMBH, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS, LUXEMBOURG INSTITUTE OF HEALTH, INSTITUT CURIE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III, CNIOInventors: Jerome Garin, Christophe Masselon, Antonia Vlahou, Manousos Makrydakis, Ieronimos Zoidakis, Bruno Domon, Elodie Duriez, Aurelie Kamoun, Francois Radvanyi, Yves Allory, Nuria Malats Riera, Mirari Marquez Cid, Magali Court
-
Patent number: 11261434Abstract: The invention provides compositions and methods useful for the treatment and prevention of conditions associated with myocardial infarction.Type: GrantFiled: August 4, 2015Date of Patent: March 1, 2022Assignees: Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO), Universität Autónoma de BarcelonaInventors: Maria Antonia Blasco Marhuenda, Bruno Bernardes De Jesus, Christian Baer, Rosa María Serrano Ruiz, Fàtima Bosch I Tubert, Eduard Ayuso, Ivan Formentini, Maria Bobadilla, Jacques Mizrahi
-
Publication number: 20210260169Abstract: The invention provides compositions and methods useful for the treatment and prevention of conditions associated with short telomere length.Type: ApplicationFiled: March 2, 2021Publication date: August 26, 2021Applicants: Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S., Universitat Autònoma de BarcelonaInventors: Maria Bobadilla, Ivan Formentini, Maria Antonia Blasco Marhuenda, Christian Baer, Fàtima Bosch Tubert
-
Publication number: 20210147804Abstract: Method for expanding stemness and differentiation potential of pluripotent cells. The invention is based on the finding that increasing micro RNA-203 levels in induced pluripotent stem (iPSCs) or embryonic stem (ESCs) cells improves the quality cell fate potential and ability of these cells to differentiate into multiple cell lineages and to reach further maturation properties without interfering with their self-renewal properties. This effect is mediated through the mi R-203-dependent control of de novo DNA methyltransferases Dnmt3a and Dnmt3b, which in turn regulate the methylation landscape of pluripotent cells. The effect can be achieved by overexpression of micro RNA-203 or by adding micro RNA-203 or analogues thereof to the cell culture medium and can be observed using a variety of cellular and in vivo models.Type: ApplicationFiled: May 25, 2018Publication date: May 20, 2021Applicant: FUNDACIÓN DEL SECTOR PÚBLICO ESTATAL CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (F.SInventors: Marcos MALUMBRES, María SALAZAR-ROA, Marianna TRAKALA, Mónica ALVAREZ-FERNANDEZ
-
Publication number: 20200123607Abstract: Methods are for detecting cells over-expressing of Programmed Death Ligand 2 (PD-L2), in particular, damaged and/or senescent cells, and the identification thereof. Antagonists of Programmed Death Ligand 2 (PD-L2) and Programmed Cell Death Protein 1 (PD-1) interaction, or inhibitors of PD-1 or PD-L2 expression are used to eliminate damaged and/or senescent cells, which are involved in numerous pathologies and aging, and are also produced as a result of exposure to toxic substances.Type: ApplicationFiled: June 29, 2018Publication date: April 23, 2020Applicant: FUNDACIÓN DEL SECTOR PÚBLICO ESTATAL CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (F.S.Inventors: Manuel SERRANO MARUGAN, Susana LLANOS GIRÓN, Andy Selim CHAIB
-
Publication number: 20190134077Abstract: Process for the identification of compounds for treating cancer. The invention relates to a method for identifying candidate compounds for use as therapeutic agents for the treatment of cancer, among those who are able to activate the MDA-5 protein or increase NOXA protein levels and to trigger autophagy. It is based on the fact that activation of dsRNA sensor MDA-5 is able to trigger the destruction of cancer cells by activation both autophagy and apoptosis, autonomously and selectively in tumor cells, without provoking the stabilization of the natural antagonist NOXA, MCL-1. The invention also relates to the use of double-stranded RNAs of the same or similar nature such as polyinosinic-polycytidylic acid (pIC), complexed with carriers such as polyethylenimine polycation (PEI), for the manufacture of medicines for the treatment of cancer.Type: ApplicationFiled: September 12, 2018Publication date: May 9, 2019Applicant: FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS CARLOS IIIInventors: Maria Soledad SOENGAS GONZÁLEZ, Damiá TORMO CARULLA
-
Publication number: 20190117685Abstract: Process for the identification of compounds for treating cancer. The invention relates to a method for identifying candidate compounds for use as therapeutic agents for the treatment of cancer, among those who are able to activate the MDA-5 protein or increase NOXA protein levels and to trigger autophagy. It is based on the fact that activation of dsRNA sensor MDA-5 is able to trigger the destruction of cancer cells by activation both autophagy and apoptosis, autonomously and selectively in tumor cells, without provoking the stabilization of the natural antagonist NOXA, MCL-1. The invention also relates to the use of double-stranded RNAs of the same or similar nature such as polyinosinic-polycytidylic acid (pIC), complexed with carriers such as polyethylenimine polycation (PEI), for the manufacture of medicines for the treatment of cancer.Type: ApplicationFiled: December 11, 2018Publication date: April 25, 2019Applicant: FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS CARLOS IIIInventors: Maria Soledad SOENGAS GONZÁLEZ, Damiá TORMO CARULLA
-
Patent number: 10208056Abstract: There is provided compounds of formula I, wherein R1, R2, R3 R4, R5, R6, R7a and R7b have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. CDK8 and/or Haspin kinase) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.Type: GrantFiled: August 25, 2016Date of Patent: February 19, 2019Assignee: FUNDACIÓN DEL SECTOR PÚBLICO ESTATAL CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (F.S.P. CNIO)Inventors: Joaquín Pastor Fernández, Sonia Martínez González, Carmen Blanco-Aparicio, Ana Isabel Hernández Higueras, Cristina Ana Gómez De La Oliva, Virginia Rivero Buceta, Rosario Concepción Riesco Fagundo
-
Patent number: 9993554Abstract: The first aspect of the invention relates to a phosphoinositide 3-kinase inhibitor for use in the treatment or prevention of a disease or condition associated with the expression of peroxisome proliferator-activated receptor gamma coactivator 1-? (Pgd1?) and/or uncoupling protein 1 (Thermogenin/Ucp1) in brown adipocytes. The disease or condition may be positive energy imbalance-associated, for example, obesity, an obesity-associated disease or condition, steatosis and biological aging (performance aging). Another aspect of the invention provides the use of a phosphoinositide 3-kinase inhibitor for promoting weight loss in an individual.Type: GrantFiled: June 1, 2011Date of Patent: June 12, 2018Assignee: CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO)Inventors: Manuel Serrano Marugan, Joaquin Pastor Fernández, Sonia Martínez González, Ana Ortega Molina, James R. Bischoff, Julen Oyarzabal Santamarina
-
Patent number: 9682991Abstract: There is provided compounds of formula (I), wherein R1, R2, R3 and R4 have meanings given in the description (and which compounds are optionally substituted as indicated in the description), and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PIM family kinase, such as PIM-1, PIM-2 and/or PIM-3) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease. There is also provided combinations comprising the compounds of formula (I).Type: GrantFiled: December 31, 2010Date of Patent: June 20, 2017Assignee: FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS IIIInventors: Joaquín Pastor Fernández, Francisco Javier Ramos Lima, Ana Isabel Hernandez Higueras, Sonia Martínez González, Jose Ignacio Martín Hernando, Carl-Gustave Pierre Saluste, Esther Gonzalez Cantalapiedra, Carmen Blanco Aparicio, Antonio Rodríguez Hergueta, Ana Maria Garcia Collazo, Antonio Salgado Serrano, Beatriz Noya Marino
-
Patent number: 9453031Abstract: Provided are chemical entities selected from compounds of formula (I), wherein R1, R2 and m have meanings given in the description, and pharmaceutically acceptable salts, solvates and stereoisomers thereof, which are inhibitors of ATR and are potentially useful in the treatment of cancer. Further provided are pharmaceutical compositions of the chemical entities, combination products containing the chemical entities, the use of the compositions as therapeutic agents, and methods of treatment using these compositions.Type: GrantFiled: March 14, 2014Date of Patent: September 27, 2016Assignee: Fundación Centro Nacional de Investigaciones Oncológicas Carlos IIIInventors: Joaquín Pastor Fernández, Oscar Fernández-Capetillo Ruiz, Sonia Martínez González, Carmen Blanco Aparicio, María del Rosario Rico Ferreira, Luis Ignacio Toledo Lázaro, Sonsoles Rodríguez Arísteguí, Matilde Murga Costa, Carmen Varela Busto, Andrés Joaquín Lopez Contreras, Oliver Renner, María Nieto Soler, David Alvaro Cebrián Muñoz
-
Patent number: 9284334Abstract: There is provided compounds of formula I, wherein R1, R2a, R2b, R2c, X, Y, Z, R3 and ring A/B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and/or mTOR) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds.Type: GrantFiled: May 18, 2012Date of Patent: March 15, 2016Assignee: Fundación Centro Nacional de Investigaciones Oncologicas Carlos IIIInventors: Joaquin Pastor Fernández, Rosa Maria Álvarez Escobar, Rosario Concepción Riesco Fagundo, Ana Belén García García, Antonio Rodriguez Hergueta, Jose Ignacio Martín Hernando, Carmen Blanco Aparicío, David Álvaro Cebrián Muñoz
-
Patent number: 9073927Abstract: There is provided compounds of formula (I), wherein A1, A4, A4a, A5, B1, B1a, B2, B2a, B3, B3a, B4, B4a and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.Type: GrantFiled: January 24, 2011Date of Patent: July 7, 2015Assignee: FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS IIIInventors: Joaquin Pastor Fernández, Sonia Martinez Gonzalez, Rosa Maria Álvarez Escobar, Antonio Rodriguez Hergueta, Jose Ignacio Martin Hernando, Francisco Javier Ramos Lima
-
Patent number: 9062109Abstract: The present invention relates to a novel antibody against ephrin B2 and its use to detect the protein and as a medicament for inhibiting angiogenesis and lymphangiogenesis in the treatment of diseases in which these processes are implicated, for example, cancer.Type: GrantFiled: September 20, 2011Date of Patent: June 23, 2015Assignee: Fundacion Centro Nacional De Investigaciones Oncologicas (CNIO)Inventors: Jorge Luis Martinez Torrecuadrada, Maria Angeles Abengozar Infantes
-
Publication number: 20150037251Abstract: The invention relates inhibiting nucleic acids directed at mammalian homologues of the Drosophila fwe gene (Flower) and to antibodies against the respective proteins, and their use in diagnosing, preventing and treating cancer.Type: ApplicationFiled: February 18, 2013Publication date: February 5, 2015Applicants: UNIVERSITAT BERN, CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICASInventors: Christa Rhiner, Evgeniya Pertova, Jesus M. Lopez-Gay, Eduardo Moreno
-
Publication number: 20140256717Abstract: There is provided compounds of formula I, wherein R1, R2a, R2b, R2c, X, Y, Z, R3 and ring A/B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and/or mTOR) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds.Type: ApplicationFiled: May 18, 2012Publication date: September 11, 2014Applicant: Centro Nacional de Investigaciones Oncológicas (CNIO)Inventors: Joaquín Pastor Fernández, Rosa Maria Álvarez Escobar, Rosario Concepción Riesco Fagundo, Ana Belén García García, Antonio Rodríguez Hergueta, Jose Ignacio Martin Hernando, Carmen Blanco Aparicio, David Álvaro Cebrián Muñoz
-
Patent number: 8815918Abstract: There is provided compounds of formula (I): wherein R1, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K) is desired and/or required, and particularly in the treatment of cancer.Type: GrantFiled: April 1, 2010Date of Patent: August 26, 2014Assignee: Centro Nacional de Investigaciones Oncologicas (CNIO)Inventors: Joaquin Pastor Fernández, Guido Kurz, Sonia Martinez Gonzalez
-
Patent number: 8778935Abstract: There is provided compounds of formula (I), wherein R1, R2, R3, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.Type: GrantFiled: April 16, 2010Date of Patent: July 15, 2014Assignee: Centro Nacional de Investigaciones Oncologicas (CNIO)Inventors: Joaquin Pastor Fernández, Sonia Martínez Gonzalez, Julen Oyarzabal Santamarina
-
Publication number: 20140154202Abstract: Process for the identification of compounds for treating cancer. The invention relates to a method for identifying candidate compounds for use as therapeutic agents for the treatment of cancer, among those who are able to activate the MDA-5 protein or increase NOXA protein levels and to trigger autophagy. It is based on the fact that activation of dsRNA sensor MDA-5 is able to trigger the destruction of cancer cells by activation both autophagy and apoptosis, autonomously and selectively in tumor cells, without provoking the stabilization of the natural antagonist NOXA, MCL-1. The invention also relates to the use of double-stranded RNAs of the same or similar nature such as polyinosinic-polycytidylic acid (pIC), complexed with carriers such as polyethylenimine polycation (PEI), for the manufacture of medicines for the treatment of cancer.Type: ApplicationFiled: May 28, 2013Publication date: June 5, 2014Applicant: FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS CARLOS IIIInventors: María Soledad SOENGAS GONZÁLEZ, Damià TORMO CARULLA